REGENXBIO Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
RGNX$8.07+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except per share data)
| As of December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $34,466 | $57,526 |
| Marketable securities | 195,604 | 177,161 |
| Accounts receivable | 26,379 | 20,473 |
| Prepaid expenses | 11,927 | 9,067 |
| Other current assets | 12,905 | 13,774 |
| Total current assets | 281,281 | 278,001 |
| Marketable securities | 10,785 | 10,179 |
| Accounts receivable | 2,312 | 474 |
| Property and equipment, net | 104,855 | 117,589 |
| Operating lease right-of-use assets | 47,156 | 53,716 |
| Restricted cash | 2,030 | 2,030 |
| Other assets | 4,613 | 4,000 |
| Total assets | $453,032 | $465,989 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $21,358 | $22,798 |
| Accrued expenses and other current liabilities | 38,390 | 38,070 |
| Deferred revenue | 10,452 | 115 |
| Operating lease liabilities | 8,286 | 7,902 |
| Royalty monetization liabilities | 39,609 | 34,309 |
| Total current liabilities | 118,095 | 103,194 |
| Deferred revenue | 18,943 | — |
| Operating lease liabilities | 65,215 | 74,131 |
| Royalty monetization liabilities | 147,408 | 25,378 |
| Other liabilities | 638 | 3,635 |
| Total liabilities | 350,299 | 206,338 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock; $0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024 | — | — |
| Common stock; $0.0001 par value; 100,000 shares authorized at December 31, 2025 and 2024; 50,892 and 49,549 shares issued and outstanding at December 31, 2025 and 2024, respectively | 5 | 5 |
| Additional paid-in capital | 1,229,442 | 1,192,536 |
| Accumulated other comprehensive loss | (687) | (741) |
| Accumulated deficit | (1,126,027) | (932,149) |
| Total stockholders’ equity | 102,733 | 259,651 |
| Total liabilities and stockholders’ equity | $453,032 | $465,989 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.